The stock of REMSleep Holdings Inc [OTCPINK: RMSL] was down -12.00% to $0.0176 at the previous close. REMSleep stock recorded volume of 4.69M shares compared to its 30-day average volume of 5.68M shares. RMSL stock price ranged from $0.0012 to $0.0472 in the past 52 weeks. Since the RMSL stock has risen in spite of lack of news, recent developments can be useful in gaining insight into the RMSL.
How did RMSL fare recently?
REMSleep manufactures medical devices aimed at giving patients with obstructive sleep apnea a better treatment experience forever. RMSL’s primary focus is designing and manufacturing products to treat sleep apnea and other respiratory problems. RMSL’s team has over 30 years of CPAP therapy experience, so they are well-versed in this therapy and the challenges of compliance.
REMSleep announced this month that it has engaged Empirical Technologies Corp (ETC) to assist it with the 510K process.
- As a result of slow progress in its 510K submission, RMSL has become frustrated.
- RMSL’s 510K submission will be streamlined by partnering with ETC, which will ensure the 510K submission gets to the right place.
- REMSleep plans to work with ETC on all future regulatory matters.
- The RMSL acknowledged that ETC submissions for 510K approval were approved 20% to 40% faster than industry average.
- RMSL is confident in ETC’s ability to submit 510K’s since it has a 100% success rate.
- The utility patent application filed by REMSleep in April 2021 has been approved.
Why is RMSL focusing so much on filing?
Remsleep (RMSL) will launch a marketing campaign for its utility patent once the 510k clearance process has been completed. Future products will be released with greater ease and speed as RMSL continues to develop new products.
